Poseida Therapeutics

Poseida Therapeutics

  • Founded: 2015
  • Location: San Diego, CA
  • Employee range: 200 - 500
  • Clinical stage: Clin1
  • Therapy area: Multiple myeloma
  • Drug types: ONC, HEM, GEN, RAR
  • Lead product: P-BCMA-ALL01 (partner: Roche)
  • Product link: https://poseida.com/pipeline/
  • Funding: $80.5M stock Aug 2022; $258M IPO Jul 2020; $110M D Jun 2020; $142M Apr 2019; $30.5M B Apr 2018
  • Investors: Novartis



job board

Short description:

Genome Editing Technologies

Drug notes:

P-MUC1C-ALL01 Clin1 solid tumors; P-CD19CD20-ALLO1 Clin1 B-cell malignancies (partner: Roche); 4 programs Clin0 multiple cancers; P-OTC-101 Clin0 OTC deficiency; P-FVIII-101 Clin0 hemophilia A; P-PAH-101 Clin0 phenylketonuria

Long description:

Poseida Therapeutics is developing next-generation gene engineering technologies. Using their proprietary genetic engineering platform combining the piggyBac DNA Modification System, Cas-CLOVER Gene Editing System and Nanparticle/AAV Delivery Technology, Poseida is developing single treatment cures that efficiently deliver genetic cargo into cells. Poseida’s gene engineering technologies represent the next wave of innovation and brings hope to patients with cancer and genetic disease. Poseida is advancing product candidates including CAR-T therapies to harness the power of a patient’s own immune system.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com